ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer

Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India.